Department of Cardiology, First Hospital of China Medical University, Shenyang, Liaoning, China.
Key Laboratory of Medical Cell Biology, Ministry of Education, Institute of Translational Medicine, Liaoning Province Collaborative Innovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, China Medical University, Shenyang, Liaoning, China.
Cell Death Differ. 2020 Sep;27(9):2605-2619. doi: 10.1038/s41418-020-0523-2. Epub 2020 Mar 5.
The elevated expression of poly(ADP-ribose) polymerase-1 (PARP1) and increased PARP1 activity, namely, poly(ADP-ribosyl)ation (PARylation), have been observed in cardiac remodeling, leading to extreme energy consumption and myocardial damage. However, the mechanisms underlying the regulation of PARP1 require further study. WWP2, a HECT-type E3 ubiquitin ligase, is highly expressed in the heart, but its function there is largely unknown. Here, we clarified the role of WWP2 in the regulation of PARP1 and the impact of this regulatory process on cardiac remodeling. We determined that the knockout of WWP2 specifically in myocardium decreased the level of PARP1 ubiquitination and increased the effects of isoproterenol (ISO)-induced PARP1 and PARylation, in turn aggravating ISO-induced myocardial hypertrophy, heart failure, and myocardial fibrosis. Similar findings were obtained in a model of ISO-induced H9c2 cells with WWP2 knockdown, while the reexpression of WWP2 significantly increased PARP1 ubiquitination and decreased PAPR1 and PARylation levels. Mechanistically, coimmunoprecipitation results identified that WWP2 is a novel interacting protein of PARP1 and mainly interacts with its BRCT domain, thus mediating the degradation of PARP1 through the ubiquitin-proteasome system. In addition, lysine 418 (K418) and lysine 249 (K249) were shown to be of critical importance in regulating PARP1 ubiquitination and degradation by WWP2. These findings reveal a novel WWP2-PARP1 signal transduction pathway involved in controlling cardiac remodeling and may provide a basis for exploring new strategies for treating heart disorders related to cardiac remodeling.
聚(ADP-核糖)聚合酶-1(PARP1)的表达升高和 PARP1 活性增加,即聚(ADP-核糖基)化(PARylation),已在心脏重构中观察到,导致极端的能量消耗和心肌损伤。然而,PARP1 调节的机制需要进一步研究。WWP2 是一种 HECT 型 E3 泛素连接酶,在心脏中高度表达,但它在那里的功能在很大程度上是未知的。在这里,我们阐明了 WWP2 在 PARP1 调节中的作用以及这一调节过程对心脏重构的影响。我们确定,心肌特异性敲除 WWP2 会降低 PARP1 泛素化水平,并增加异丙肾上腺素(ISO)诱导的 PARP1 和 PARylation 的作用,进而加重 ISO 诱导的心肌肥大、心力衰竭和心肌纤维化。在 ISO 诱导的 H9c2 细胞模型中,敲低 WWP2 也得到了类似的发现,而 WWP2 的重新表达显著增加了 PARP1 泛素化水平,降低了 PARP1 和 PARylation 水平。从机制上讲,免疫共沉淀结果表明 WWP2 是 PARP1 的一种新型相互作用蛋白,主要与 PARP1 的 BRCT 结构域相互作用,从而通过泛素-蛋白酶体系统介导 PARP1 的降解。此外,赖氨酸 418(K418)和赖氨酸 249(K249)被证明在调节 PARP1 泛素化和降解方面至关重要。这些发现揭示了一种新的 WWP2-PARP1 信号转导途径,涉及控制心脏重构,并可能为探索与心脏重构相关的心脏疾病治疗的新策略提供依据。